Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
ULTRAM is an oral tablet small-molecule analgesic approved in 1995 by Johnson & Johnson. The mechanism of action and specific indications are not documented in available data, limiting characterization of its therapeutic positioning. As an NDA-approved product now approaching loss of exclusivity, it represents a mature franchise in pharmaceutical portfolios.
Moderate competitive pressure (30/100) suggests the product faces headwinds; commercial teams should anticipate headcount rationalization or transition to LOE-defensive strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants
A Study of ULTRAM ER at Two Dose Levels in Adolescents With Pain
A Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER in Children With Pain
Worked on ULTRAM at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked job openings signal that ULTRAM is a low-priority or maintenance asset within J&J's portfolio; career progression on this product is limited. Professionals seeking growth should prioritize newer, growth-stage assets or consider transition roles in generic defense or portfolio optimization.